Influence of the preparation method on the physicochemical properties of econazole-β-cyclodextrin complexes

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 60, Issue 1-2, 2008, Pages 85-93

  Al Marzouqi, Ali H ^a   Solieman, Ayser ^a   Shehadi, Ihsan ^a   Adem, Abdu ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Cyclodextrin; Econazole; Inclusion complex; Supercritical carbon dioxide

Indexed keywords

EID: 38349115957     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-007-9356-6     Document Type: Article

References (35)

1. Hughes, W.T., Bartley, D.L., Patterson, G.G., Tufenkeji, H.: Ketoconazole and candidiasis: a controlled study. J. Infect. Dis. 147, 1060-1063 (1983)
2. Murray, P.A., Koletar, S.L., Mallegol, I., Wu, J., Moskovitz, B.L.: Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin. Ther. 19, 471-480 (1997)
3. Hay, R.J.: Overview of studies of fluconazole in oropharyngeal candidiasis. Rev. Infect. Dis. 12(suppl. 3), S334-S337 (1990)
4. Meunier, F., Aoun, M., Gerard, M.: Therapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole. Rev. Infect. Dis. 12(suppl. 3), S364-S368 (1990)
5. Darouiche, R.O.: Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26, 259-274 (1998)
6. Pons, V., Greenspan, D., Lozada-Nur, F., McPhail, L., Gallant, J.E., Tunkel, A., Johnson, C.C., McCarty, J., Panzer, H., Levenstein, M., Barranco, A., Green, S.: Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin. Infect. Dis. 24, 1204-1207 (1997)
7. Szejtli, J.: Cyclodextrins in drug formulations: Part II. Pharm. Technol. Int. Aug., 24-38 (1991)
8. Duchene, D., Wouessidjewe, D.: Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Part II. Pharm. Technol. Aug., 22-30 (1990)
9. Nambu, N., Kikuchi, K., Kikuchi, T., Takahashi, Y., Ueda, H., Nagai, T.: Influence of inclusion of nonsteroidal antiinflammatory drugs with β-cylcodextrin on the irritation to stomach of rats upon oral administration. Chem. Pharm. Bull. 26(12), 3609-3612 (1978)
10. Dhanaraju, M.D., Kumaran, K.S., Baskaran, T., Moorthy, M.S.R.: Enhancement of bioavailability of Griseofulvin by its complexation with β-cyclodextrin. Drug Dev. Ind. Pharm. 24(6), 583-587 (1998)
11. Hostetler, J.S., Hanson, L.H., Stevens, D.A.: Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob. Agents Chemother. 36(2), 477-480 (1992)
12. Jacobsen, J., Bjerregaard, S., Pedersen, M.: Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity-drug supersaturation, toxicity on TR146 cells and release from a delivery system. Eur. J. Pharm. Biopharm. 48(3), 217-224 (1999)
13. Lee, B., Lee, J.: Enhancement of solubility and dissolution rate of poorly water-soluble Naproxen by complexation with 2-hydroxypropyl-β- cyclodextrin. Arch. Pharm. Res. 18(1), 22-26 (1995)
14. Lee, S.Y., Chun, I.K.: Design of new parenteral aqueous formulations of fluconazole by the use of modified cyclodextrins. Yakhak Hoechi. 45(4), 357-365 (2001)
15. Mura, P., Adragna, E., Rabasco, A.M., Moyano, J.R., Perez-Martinez, J.I., Arias, M.J., Gines, J.M.: Effect of the host cavity size and the preparation method on the physicochemical properties of Ibuproxam-cyclodextrin systems. Drug Dev. Ind. Pharm. 25(3), 279-287 (1999)
16. Mura, P., Faucci, M.T., Manderioli, A., Bramanti, G.: Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins. Int. J. Pharm. 193(1), 85-95 (1999)
17. Strickley, R.: Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230 (2004)
18. Loftsson, T., Masson, M., Brewster, M.: Self-association of cyclodextrins and cyclodextrin complexes. J. Pharm. Sci. 93, 1091-1099 (2004)
19. Peeters, J., Neeskens, P., Tollenaere, J., Remoortere, P.V., Brewstrer, M.E.: Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with Itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91(6), 1414-1422 (2002)
20. Van Hees, T., Piel, G., Evrard, B., Otte, X., Thunus, L., Delattre, L.: Application of supercritical carbon dioxide for the preparation of a Piroxicam-β-cyclodextrin inclusion compound. Pharm. Res. 16(12), 1864-1870 (1999)
21. Van Hees, T., Barillaro, V., Piel, G., Bertholet, P., De Hassonville, S., Evrard, B., Delattre, L.: Application of supercritical carbon dioxide for the preparation of drug-cyclodextrin inclusion compounds. J. Incl. Phenom. Macro. 44, 271-274 (2002)
22. Bandi, N., Wei, W., Roberts, C.B., Kotra, L.P., Kompella, U.B.: Preparation of budesonide-and indomethacin-hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci. 23, 159-168 (2004)
23. Fabing, I., Leboeuf, F., Jung, J., Perrut, M.: Method for making very fine particles consisting of a principle inserted in a host-molecule. Patents FR 2 815 540- WO 0232462- EP 1 330 266, 2000
24. Perrut, M., Jung, J., Leboeuf, F.: Enhancement of dissolution rate of poorly soluble active ingredients by supercritical fluid processes, Part II: preparation of composite particles. Int. J. Pharm. 288, 11-16 (2005)
25. Rodier, E., Lochard, H., Sauceau, M., Letourneau, J.-J., Freiss, B., Fages, J.: A three step supercritical process to improve the dissolution rate of Eflucimibe. Eur. J. Pharm. Sci. 26, 184-193 (2005)
26. Al-Marzouqi, A.H., Jobe, B., Dowaidar, A., Maestrelli, F., Mura, P.: Evaluation of supercritical fluid technology as preparative technique of benzocaine-cyclodextrin complexes-Comparison with conventional methods. J. Pharm. Biomed. Anal. 43, 566-574 (2007)
27. Al-Marzouqi, A.H., Jobe, B., Corti, G., Cirri, M., Mura, P.: Physicochemical characterization of drug-cyclodextrin complexes prepared by supercritical carbon dioxide and by conventional techniques. J. Incl. Phenom. Macro. 57, 223-231 (2007)
28. Al-Marzouqi, A.H., Shehatta, I., Jobe, B., Dowaidar, A.: Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide. J. pharm. Sci. 95(2), 292-304 (2006)
29. Shehatta, I., Al-Marzouqi, A.H., Jobe, B., Dowaidar, A.: Enhancement of aqueous solubility of itraconazole by complexation with cyclodextrins using supercritical carbon dioxide. Can. J. Chem. 83(10), 1833-1838 (2005)
30. Hassan, A., Tang, Y., Ayres, J.: Itraconazole formation using supercritical carbon dioxide. Drug Dev. Ind. Pharm. 30(10), 1029-1035 (2004)
31. Kiran, E., Brennecke, J.: Supercritical Fluid Engineering Science, ACS Symposium Series 514. American Chemical Society, Washington, D.C. (1993)
32. Charoenchaitrakool, M., Dehghani, F., Foster, N.R.: Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin. Int. J. Pharm. 239, 103-112 (2002)
33. Türk, M., Upper, G., Steurenthaler, M., Hussein, Kh., Wahl, M.A.: Complex formation of ibuprofen and β-cyclodextrin by controlled particle deposition (CPD) using SC-CO2. J. Supercrit. Fluids 39, 435-443 (2007)
34. Pedersen, M., Edelsten, M., Nielsen, V.F., Scarpellini, A., Skytte, S., Slot, C.: Formation and antimycotic effect of cyclodextrin inclusion complexes of econazole and miconazole. Int. J. Pharm. 90, 247-254 (1993)
35. Pedersen, M., Bjerregaard, S., Jacobsen, J., Larsen, A.R., Sørensen, A.M.: An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example. Int. J. Pharm. 165, 57-68 (1998)